ClearPoint Neuro Q1 revenue $5.0M, up 25% YoY; raises FY2022 guidance to $21-22M

ClearPoint Neuro, Inc.

2022-Q1 EPS reported -$0.17 revenue$5,031,000

Record quarterly revenue of $5.0M, a 25% increase vs Q1 2021.
Biologics and drug delivery revenue $2.2M (+30% YoY); functional neurosurgery revenue $2.2M (+17%).
Operating expenses $7.1M, up from $4.8M in Q1 2021, driven by headcount and R&D.
Cash position $49.7M at March 31, 2022 vs $54.1M at year-end 2021.
Raised FY2022 revenue guidance to $21.0-22.0M, representing 30-35% growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.